1. We target Cryptic (Silent) Microbial Natural Products

OUR PROPRIETARY KEYS UNLOCK NEW BIOTECH APPLICATIONS FROM UNTAPPED MICROBIAL NATURAL PRODUCTS

The potential for discovering new pharmaceutical drugs from natural products of microbial origin (such as fungi, bacteria and microalgae) is still largely unexploited, mainly because the keys to unlock the production of most microbial natural products are not yet understood.

Around 99% of all bacterial species are as yet unculturable, and microbial genomic studies of fungi and culturable bacteria suggest there are overwhelming number of “silent” (cryptic) natural products still unknown to science.

DISRUPTION FROM THE PAST

At ENDOBIOS, we specialize in validating novel approaches, as yet unknown in the field of microbial natural products.

ENDOBIOS was founded following 15+ years’ experience in drug discovery from microbial sources, a departure from traditional approaches.

We don’t use single-strain cultivations in different culture media (where’s the stimuli?), epigenetics, co-cultivations, adsorbent resins nor genome mining. We won’t use traditionally ineffective, non-disease oriented microbial cultivations, non-reproducible, expensive approaches or those not applicable for high throughput screening (HTS).

ENDOBIOS DISRUPTIVE NATURAL PRODUCTS DISCOVERY FROM MICROBES:

We focus our efforts on earlier stage discovery, by understanding how to custom-challenge microorganisms. Our intellectual property is unique.

WHAT WE DO:

Besides the two drug leads we have in the pipeline, ENDOBIOS is consolidating disruptive methods for activating disease-targeted silent natural products from microbial cultures by applying custom induction keys, based on discoveries of microbial behaviour and response mechanisms.

  • We use single-culture medium
  • We focus on induced compounds
  • We also target the 99% of bacteria which are currently unculturable
  • We work with any organism culturable in the lab (whether fungi, bacteria or microalgae)
  • We focus on High Throughput Screening (HTS)
  • We focus on cost-effective design
  • We focus on innovative approaches
  • We focus on microbial symbioses to elicit bioactive natural compounds

Contact us for further information.